CLOVHIGH SIGNALFINANCIAL10-K

Clover Health shows deteriorating profitability despite revenue growth, with substantially higher losses and a significant cash position decline.

The company's financial trajectory is concerning as losses roughly doubled while cash reserves declined by nearly 60% to $78.3M, raising questions about runway and capital efficiency. Despite meaningful revenue expansion to $1.9B, the inability to control operating losses suggests fundamental challenges in the business model that investors should monitor closely.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

Clover Health presents a mixed but troubling financial picture with revenue growing meaningfully to $1.9B while operating losses substantially expanded, indicating deteriorating unit economics. The company's cash position declined sharply from $194.5M to $78.3M, representing a significant reduction in financial flexibility. Interest expense nearly disappeared, but this positive development was overwhelmed by the substantial increase in operating losses, suggesting operational challenges are outweighing any improvements in capital structure.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-99.5%
$1.3M$7K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
-98.9%
-$43.0M-$85.5M

Net income declined 98.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-87%
-$45.7M-$85.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-59.8%
$194.5M$78.3M

Cash declined 59.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
+40.3%
$1.4B$1.9B

Strong top-line growth of 40.3% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-35.1%
$535.4M$347.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
+31.3%
$1.6M$2.0M

Capital expenditure jumped 31.3% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
-10.3%
$343.1M$307.9M

Current assets declined 10.3% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
clov-20251231 0001801170 FALSE FY 2025 CLOVER HEALTH INVESTMENTS, CORP.
At February 20, 2026, the registrant had 428,951,430 shares of Class A Common Stock, $0.0001 par value per share, and 95,715,856 shares of Class B Common Stock, $0.0001 par value per share, issued and outstanding.
Reserved 57 Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations 58 Item 7A.
Our long-term success depends on maintaining and continuing to improve CA, and the expansion of CA to external partners, as such, our past results may not be indicative of future performance.
Our strategy is to improve the care of our Medicare Advantage ("MA") members, develop wide physician networks, and provide technology to help empower physicians.
+7 more — sign up free →
REMOVED
clov-20241231 0001801170 FALSE FY 2024 CLOVER HEALTH INVESTMENTS, CORP.
At February 24, 2025, the registrant had 418,531,705 shares of Class A Common Stock, $0.0001 par value per share, and 92,375,003 shares of Class B Common Stock, $0.0001 par value per share, issued and outstanding.
Reserved 59 Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.
Our long-term success depends on maintaining and continuing to improve Clover Assistant, and our past results may not be indicative of future performance.
Our future performance depends in part on increasing the lifetime value of enrollments, which are realized over several years, and utilizing our clinical care capabilities to improve the quality of care for our members, and any failure to do so could negatively affect our financial condition and results of operations, including our ability to achieve or increase profitability.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →